Literature DB >> 2470505

Auto-tumor lysis by blood lymphocytes in vitro. Strongly activated lymphocytes lack selectivity.

F Vánky1, E Klein.   

Abstract

Selectivity of the lysis of the tumor cells by autologous blood lymphocytes and its various subsets was investigated by means of the cold target competition assay. The effectors were autologous lymphocytes passed through a nylon-wool column (unfractionated: U) and their low- and high-density subsets, either without or after activation. The lymphocytes were activated (a) in autologous mixed lymphocyte tumor cell culture in autologous (MLTC), (b) in mixed lymphocyte culture (MLC), without and with interleukin-2, for 6 days, or (c) by phytohaemagglutinin for 3 days. Autologous-lymphocyte-mediated cytotoxicity (auto-tumor lysis: ALC) by the unfractionated, unmanipulated blood lymphocyte (U) population, its high-density fraction and those induced for auto-tumor lysis in the MLTC is regularly weak and affects only the autologous tumor cells. Their ALC function was inhibited only by the target identical unlabelled cells while the effect of separated low-density lymphocytes was inhibited also by allogeneic tumor cells. The cold-target competition assay indicated that several subsets with different specificities exist simultaneously in the effector populations activated in MLC, because the various targets did not cross-compete or did so only partially. Whenever interleukin-2 was added, at the start of the mixed cultures (MLTC or MLC), the lytic effects were no longer selective. Phytohaemagglutinin-activated effectors lysed several targets. These targets were inhibitory in a criss-cross fashion. Generally, populations showing auto-tumor selectivity had weak lytic effects, while the strongly activated effectors, with strong cytotoxic function, were not selective.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470505     DOI: 10.1007/bf00199287

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  34 in total

Review 1.  Integrins: a family of cell surface receptors.

Authors:  R O Hynes
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

2.  Lysis of syngeneic solid tumor cells by alloantigen stimulated mouse T and non-T cells.

Authors:  P A Paciucci; S Macphail; J M Zarling; F H Bach
Journal:  J Immunol       Date:  1980-01       Impact factor: 5.422

3.  Tumor biopsy cells participating in systems in which cytotoxicity of lymphocytes is generated. Autologous and allogeneic studies.

Authors:  F Vánky; S Argov; E Klein
Journal:  Int J Cancer       Date:  1981-03-15       Impact factor: 7.396

4.  Manipulation of graft-versus-host disease for a graft-versus-leukemia effect after allogeneic bone marrow transplantation in AKR mice with spontaneous leukemia/lymphoma.

Authors:  R L Truitt; C C Shih; A V LeFever
Journal:  Transplantation       Date:  1986-03       Impact factor: 4.939

5.  Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization.

Authors:  A Mazumder; E A Grimm; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

6.  Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.

Authors:  D S Heo; T L Whiteside; A Kanbour; R B Herberman
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

7.  Human tumor-lymphocyte interaction in vitro. VI. Specificity of primary and secondary autologous lymphocyte-mediated cytotoxicity.

Authors:  F T Vánky; B M Vose; M Fopp; E Klein
Journal:  J Natl Cancer Inst       Date:  1979-06       Impact factor: 13.506

8.  Lysis of autologous tumor cells by blood lymphocytes tested at the time of surgery. Correlation with the postsurgical clinical course.

Authors:  F Vánky; E Klein; J Willems; K Böök; T Ivert; A Péterffy; U Nilsonne; A Kreicbergs; T Aparisi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  Role of alloantigens in natural killing. Allogeneic but not autologous tumor biopsy cells are sensitive for interferon-induced cytotoxicity of human blood lymphcoytes.

Authors:  F T Vánky; S A Argov; S A Einhorn; E Klein
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307

10.  Restricted autologous lymphocytotoxicity in lung neoplasia.

Authors:  B M Vose; F Vánky; M Fopp; E Klein
Journal:  Br J Cancer       Date:  1978-09       Impact factor: 7.640

View more
  4 in total

1.  Killer cells induced by stimulation with allogeneic tumor cells and subsequent culture with recombinant interleukin-2.

Authors:  T Fukiage; H Murakami; M Eura; T Ikawa; T Ishikawa
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Feeder cells enhance oncolytic and proliferative activity of long-term human bone marrow interleukin-2 cultures and induce different lymphocyte subsets.

Authors:  P R Fuchshuber; E Lotzová
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro.

Authors:  F Vánky; P Wang; M Patarroyo; E Klein
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Immunogenicity and immunosensitivity of ex vivo human carcinomas: interferon gamma and tumour necrosis factor alpha treatment of tumour cells potentiates their interaction with autologous blood lymphocytes.

Authors:  F Vánky; C Hising; K Sjöwall; B Larsson; L Rodriguez; L Orre; E Klein
Journal:  Cancer Immunol Immunother       Date:  1995-10       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.